FDA approves new pancreatic cancer drug that could extend patients' lives
Patients taking the first-of-a-kind pill, called daraxonrasib, lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients, studies showed.
CBS News5 sources
First coverage · Latest coverage
Compiled by CurrentWire News Desk
Summary based on reporting from CBS News, ABC News, NBC News, France 24 and STAT.
Coverage at a glance
- First observed by CurrentWire: STAT · Aug 26, 2026 at 10:56 AM ET
- Coverage span: 9h 11m
- Coverage: 8 reports from 5 independent publications
In this story
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
8 reports from 5 publications.
Excerpts are the summaries each publisher distributes with its own feed, shortened and attributed.
CBS NewsTier B
FDA approves new pancreatic cancer drug that could extend patients' lives(opens original report in a new tab)NBC NewsTier B
FDA approves breakthrough pancreatic cancer treatment(opens original report in a new tab)The Food and Drug Administration approved a breakthrough pancreatic cancer treatment, found to double survival to thirteen months compared to people who just got chemotherapy. It's called Rasonque, and it's approved for… — NBC News
France 24Tier B
FDA approves new drug Rasonque to treat advanced pancreatic cancer(opens original report in a new tab)The US FDA on Wednesday approved Revolution Medicines' Rasonque for advanced pancreatic cancer, opening a new treatment option for patients with metastatic disease. A large trial found the once-daily pill doubled… — France 24
ABC NewsTier B
FDA approves landmark pancreatic cancer drug that's shown to improve survival(opens original report in a new tab)U.S. health officials have approved a groundbreaking pancreatic cancer drug that offers a new approach to treating the deadly form of cancer — ABC News
ABC NewsTier B
FDA approves landmark pancreatic cancer drug that's shown to improve survival(opens original report in a new tab)U.S. health officials have approved a groundbreaking pancreatic cancer drug that offers a new approach to treating the deadly form of cancer — ABC News
NBC NewsTier B
FDA approves groundbreaking new drug for pancreatic cancer(opens original report in a new tab)The Food and Drug Administration approved a groundbreaking new oral drug for pancreatic patients suffering from the most aggressive form of the disease. Daraxonrasib, which targets a mutation in a gene called KRAS,… — NBC News
NBC NewsTier B
FDA approves ‘game-changing’ pancreatic cancer drug(opens original report in a new tab)In a late-stage trial, people who got Revolution Medicines’ Rasonque, or daraxonrasib, lived about twice as long as people who got standard care. — NBC News
STATTier B
STAT+: FDA approves new pancreatic cancer drug expected to usher in new era of treatment(opens original report in a new tab)The FDA has approved a life-extending treatment for advanced pancreatic cancer — the first such therapy to attack a genetic cause of the highly lethal malignancy. — STAT
How coverage developed
First report from STAT
Reported by NBC News
Reported by NBC News
Reported by ABC News
Reported by ABC News
Reported by France 24
Reported by NBC News
Reported by CBS News
How CurrentWire compiled this story
CBS News (www.cbsnews.com), a Tier B publisher, filed this report on .
Signal breakdown
CurrentWire ranked this story 86.3 of 100 in the snapshot this page was rendered from.
- Freshness
- 32.9 of 35
- Source authority
- 14 of 20
- Coverage breadth
- 14.4 of 20
- Geographic relevance
- 10 of 10
- Story prominence
- 10 of 10
- Velocity
- 5 of 5
Strongest signal: geographic relevance, 10 of 10. How each signal is calculated.
Filed under Health · United States · News. Topics extracted from this report, with other live CurrentWire stories mentioning each: FDA (3), United States (98).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.